Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to “Buy” at Wall Street Zen

Wall Street Zen lowered shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a strong-buy rating to a buy rating in a report issued on Sunday morning.

A number of other analysts also recently commented on the company. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Zacks Research lowered Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Stifel Nicolaus boosted their price target on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research report on Friday, December 19th. Finally, Craig Hallum set a $65.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $62.17.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $53.67 on Friday. Supernus Pharmaceuticals has a 12 month low of $29.16 and a 12 month high of $59.68. The firm has a market capitalization of $3.09 billion, a PE ratio of -78.93, a P/E/G ratio of 1.68 and a beta of 0.70. The company’s 50 day simple moving average is $51.12 and its 200 day simple moving average is $48.96.

Insider Buying and Selling

In other Supernus Pharmaceuticals news, Director Georges Gemayel sold 10,000 shares of the business’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $53.71, for a total transaction of $537,100.00. Following the sale, the director owned 28,159 shares in the company, valued at approximately $1,512,419.89. The trade was a 26.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 710 shares of the company’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the sale, the vice president directly owned 14,508 shares of the company’s stock, valued at $644,735.52. This represents a 4.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 43,972 shares of company stock worth $2,270,833. Company insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Large investors have recently made changes to their positions in the company. State Street Corp boosted its stake in Supernus Pharmaceuticals by 1.4% in the 4th quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company’s stock worth $110,296,000 after purchasing an additional 31,668 shares during the period. Geode Capital Management LLC grew its position in Supernus Pharmaceuticals by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company’s stock worth $73,215,000 after purchasing an additional 62,875 shares in the last quarter. Loomis Sayles & Co. L P raised its stake in Supernus Pharmaceuticals by 12.7% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company’s stock valued at $72,007,000 after purchasing an additional 162,905 shares during the period. Stephens Investment Management Group LLC raised its stake in Supernus Pharmaceuticals by 4.5% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock valued at $69,904,000 after purchasing an additional 61,120 shares during the period. Finally, Woodline Partners LP lifted its holdings in shares of Supernus Pharmaceuticals by 63.5% in the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after purchasing an additional 490,835 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.